Seres Therapeutics, Inc. (MCRB) EPS Estimated At $-0.73

February 24, 2018 - By Migdalia James

 Seres Therapeutics, Inc. (MCRB) EPS Estimated At $ 0.73

Analysts expect Seres Therapeutics, Inc. (NASDAQ:MCRB) to report $-0.73 EPS on March, 15.They anticipate $0.10 EPS change or 15.87 % from last quarter’s $-0.63 EPS. After having $-0.17 EPS previously, Seres Therapeutics, Inc.’s analysts see 329.41 % EPS growth. The stock increased 1.55% or $0.15 during the last trading session, reaching $9.81. About 94,000 shares traded. Seres Therapeutics, Inc. (NASDAQ:MCRB) has declined 64.58% since February 24, 2017 and is downtrending. It has underperformed by 81.28% the S&P500.

Seres Therapeutics, Inc. (NASDAQ:MCRB) Ratings Coverage

Among 9 analysts covering Seres Therapeutics Inc (NASDAQ:MCRB), 9 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Seres Therapeutics Inc had 23 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by H.C. Wainwright on Friday, August 4 with “Buy”. As per Thursday, October 19, the company rating was maintained by Cantor Fitzgerald. The company was maintained on Monday, June 12 by Canaccord Genuity. The firm earned “Buy” rating on Monday, January 25 by H.C. Wainwright. The firm has “Buy” rating by Canaccord Genuity given on Tuesday, August 25. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Buy” rating given on Friday, July 29 by H.C. Wainwright. Oppenheimer initiated the stock with “Buy” rating in Thursday, October 12 report. The rating was upgraded by Bank of America to “Buy” on Thursday, October 22. The stock of Seres Therapeutics, Inc. (NASDAQ:MCRB) has “Outperform” rating given on Friday, August 12 by FBR Capital. The stock has “Outperform” rating by FBR Capital on Wednesday, March 30.

Seres Therapeutics, Inc., a microbiome therapeutics platform company, engages in developing biological drugs designed to restore health by repairing the function of a dysbiotic microbiome. The company has market cap of $397.60 million. The Company’s lead product candidate is SER-109, a bacterial spore ecology, which has completed Phase II clinical study to treat multiply recurrent Clostridium difficile infection . It currently has negative earnings. The firm also develops SER-287 that is in Phase Ib clinical study in patients with mild-to-moderate ulcerative colitis; and SER-262, a synthetic microbiome therapeutic candidate, which is in Phase Ib study in patients with primary CDI.

More notable recent Seres Therapeutics, Inc. (NASDAQ:MCRB) news were published by: Businesswire.com which released: “Seres Therapeutics Announces Appointment of Eric D. Shaff to Additional Role …” on January 31, 2018, also Seekingalpha.com with their article: “Seres Therapeutics’ (MCRB) CEO Roger Pomerantz on Q3 2017 Results – Earnings …” published on November 08, 2017, Businesswire.com published: “Seres Therapeutics Awarded Grant from CARB-X to Support Development of …” on November 07, 2017. More interesting news about Seres Therapeutics, Inc. (NASDAQ:MCRB) were released by: Businesswire.com and their article: “Seres Therapeutics Reports SER-287 Phase 1b Microbiome Analyses that Provide …” published on January 04, 2018 as well as Businesswire.com‘s news article titled: “Seres Therapeutics, MD Anderson Cancer Center, and the Parker Institute for …” with publication date: November 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.